Longevity medicine, particularly in the context of Altos Labs, focuses on developing therapies that target and clear senescent cells. Senescent cells are those that have stopped dividing but remain present within tissues, contributing to age-related decline.
The primary issue addressed by Altos Labs' approach is the accumulation of senescent cells, which are linked to a variety of age-related conditions including frailty, organ dysfunction, and increased susceptibility to diseases like cancer and neurodegeneration.
Altos Labs employs methods such as small molecule inhibitors or biologics to identify and eliminate senescent cells in the body. This process is designed to reduce cellular damage associated with aging and improve overall healthspan—essentially extending the period of healthy life before the onset of significant age-related diseases.
The manufacturing process involves developing and optimizing small molecules or biologics that can selectively target senescent cells. This requires extensive testing in vitro and in vivo to ensure safety and efficacy before clinical trials.
Development of these therapies typically includes a series of steps: initial screening for potential compounds, preclinical testing, optimization of formulations, and finally, large-scale production tailored for human use.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.